Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized
nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry cancer-killing
substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood
flow to the tumor. Giving carboplatin and paclitaxel together with bevacizumab may kill more
tumor cells.
PURPOSE: This phase II trial is studying how well giving carboplatin and paclitaxel together
with bevacizumab works in treating patients with locally recurrent or metastatic breast
cancer.